Pituitary responsiveness to gonadotrophin-releasing and thyrotrophin-releasing hormones in epileptic patients receiving carbamazepine or phenytoin.
Pituitary responsiveness to gonadotrophin-releasing (LHRH) and thyrotrophin-releasing (TRH) hormones was studied in 19 epileptic patients receiving long-term carbamazepine or phenytoin therapy and 14 normal control subjects. Baseline prolactin levels were normal in the patients; 2h after LHRH-TRH the prolactin levels in women on carbamazepine were significantly higher than in the controls, but apart from this, no other differences were found. Baseline LH levels were raised in male patients and the response to LHRH-TRH was exaggerated in all patients on carbamazepine. FSH levels were normal throughout. The exaggerated LH response is consistent with primary hypogonadism caused by enhanced sex hormone metabolism, secondary to hepatic enzyme induction by the antiepileptic drugs.
D000328:Adult; D002220:Carbamazepine / Q000627:therapeutic use*; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology*; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010672:Phenytoin / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*
D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D002220:Carbamazepine; D013973:Thyrotropin-Releasing Hormone; D010672:Phenytoin; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone